Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Cerebral and Cardiac Blood Flow During Exercise in Patients With COPD (REFLEX-COPD)

28 de octubre de 2019 actualizado por: University of Nottingham

Cardiac Output and Brain Perfusion and Architecture During Exercise in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Healthy, Age Matched Volunteers

Heart disease and conditions related to the blood vessels are responsible for a large proportion (over a quarter) of the deaths in people with chronic obstructive pulmonary disease (COPD). The changes can also affect the smaller smaller blood vessels within the body, in particular the brain and the kidneys. This might be related to how the heart pumps and if it is under any pressure. Investigations performed at the University in healthy older volunteers demonstrated how the blood flows in the brain and heart during exercise. Exercise gently puts the whole body under some pressure and therefore exposes any weaker areas.

In this study the investigators are hoping to find out what happens to the blood flow in the brain and in the heart in patients who have COPD when they exercise and in the resting state. This will be compared to people of a similar age with a similar smoking history but without COPD. This will be examined using state of the art magnetic resonance imaging (MRI) and will allow us to assess whether changes in structure and function are related to this altered blood flow.

Our hypothesis is that COPD will cause a larger change in blood flow during exercise compared to the healthy volunteers and that reduced cardiorespiratory fitness will be associated with increased age related structural within the brain.

Descripción general del estudio

Estado

Desconocido

Descripción detallada

The aim is to recruit 20 participants with COPD, who will be compared to 10 age and gender matched controls who also have a smoking history. The investigators aim for this number to complete the components of the study and therefore may have to over-recruit if some people drop out or are not eligible. The study elements are feasible, as the work extends a previous research study in healthy volunteers.

This research trial will consist of a medical screening visit and three investigation study visits spaced ideally one week apart. The investigation visits will begin within 6 (ideally within 4) weeks of the medical screening visit. The total duration of the study and screening visits should be 12 weeks maximum for each participant.

Screening visit:

If the participant expresses an interest in the clinical trial and wants to take part they will be invited (at a convenient time for them) to attend a medical screening visit located at the Nottingham City hospital. Here the investigator will discuss the research trial and answer any questions or concerns they might have regarding the research trial. The participant, if willing, will then be required to sign a consent form so that the screening procedures can begin, which include:

  • Blood sample: Approximately a 20ml sample (4 teaspoons) taken from their arm, for further investigation including full blood count (FBC), brain natriuretic peptide (BNP) and kidney function.
  • Questionnaires: 5 different questionnaires that ask about symptoms and how they affect daily life, a physical activity questionnaire, quality of life questionnaire and a MRI safety questionnaire.
  • Spirometry: A simple blowing test to assess the participants' breathing which is performed three times.
  • 12 lead ECG.
  • a hand grip dynamometer to assess muscle strength
  • timed up and go test: a test used to measure gait speed, where participants are asked to get up from a chair and walking to 3 meters and back, whilst being timed.
  • to wear a step counter (Sensewear armband) for a week during waking hours to record steps.

Provided the ECG, step count (<10,000 steps) and other screening elements are ok, the participant will proceed to Study visit 1.

Strength and exercise test protocol:

The participant will be required to abstain from strenuous exercise for the 48 hours prior to the visit and also from alcohol and caffeine for 24 hours prior. Upon arrival they will perform a knee extension exercise so we can establish the muscle strength in the legs, specifically 3 maximal knee extensions with a 30 second rest in between. We will also measure fatigue by dong 20 extensions after a short break.

After a break they will then undergo an exercise test using an MRI compatible stepper device (Ergospect Cardiostepper) whilst in a supine position. This has been adapted to be similar to how they will exercise in the MRI scanner. Volunteers will start off stepping at a frequency of 65-70 steps a minute at the minimum workload and every 3 minutes get gradually a little harder until exhaustion is reached. Heart rate at rest and in response to exercise will be measured using a heart monitor. Participants will be given the option to have their expired gases also measured during exercise using a face mask, though this is not necessary if not tolerated. In the final minute of each workload we will take a finger prick test to measure the gases in the patients blood. A 3 lead ECG and oxygen saturation probe will be attached during exercise as safety measures and the protocol will be halted if oxygen saturation falls below 80% or if any relevant rhythm abnormalities are seen on the ECG trace.

The second study visit will be used to confirm the exercise and strength parameters measured in the first study visit.

MRI protocol:

A series of scans of the brain and heart will be taken at rest and then whilst stepping on the stepper machine within the MRI. The exercise will be at a steady state low level intensity determined by calculating the workload at which a fraction of maximum heart rate was achieved during first 2 study visits.

The MRI scan itself will take about ¾ hour but upto 2 hours is allowed for preparation and introducing the scan to the participant. The scanner is quite noisy and so the participant will wear ear defenders during the scan. Because the scanner is built around a large magnet, the participant will be instructed to remove all metal from their body, including jewellery. There is no radiation involved.

Tipo de estudio

De observación

Inscripción (Anticipado)

30

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Nottinghamshire
      • Nottingham, Nottinghamshire, Reino Unido, NG5 1PB
        • Reclutamiento
        • NIHR Nottingham BRC Respiratory Theme, University of Nottingham and NUH Trust
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

60 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

We are recruiting participants within the Nottinghamshire region. Specifically for patients with COPD, we are targeting outpatient respiratory clinics at the Nottingham University Hospitals Trust, inpatient admissions due to COPD exacerbation at the Nottingham City Hospital, pulmonary rehabilitation groups and respiratory focus groups within Nottingham and patients on the Nottingham Respiratory Research Unit database.

Descripción

Inclusion Criteria:

  • Patients aged 65-75 years old,
  • >10 pack years smoking,
  • FEV1/FVC <0.7 and FEV1<60% predicted (for COPD participants only)
  • Sedentary lifestyle (<10,000 steps per day)
  • Able to give informed consent
  • Able to read, understand and communicate coherently in English

Exclusion Criteria:

  • Doctor diagnosis of ischaemic heart disease or heart failure
  • Doctor diagnosis of dementia or Alzheimers disease
  • History of previous cerebrovascular disease (stroke or TIA) or malignancy
  • Pregnancy or childbearing in the last 6 months
  • Maintenance oral corticosteroids in the past 6 months
  • Requirement for oral corticosteroids or antibiotics in the past 6 weeks
  • Active arthritis or other muscular condition limiting exercise
  • Surgical intervention in the last 12 weeks
  • Long term oxygen therapy requirement
  • Other formal current respiratory diagnosis
  • Thyroid disease
  • Diabetes Mellitus
  • Neurological or cognitive impairment
  • Significant physical disability
  • Any other conditions in addition to the above that the investigators consider may affect study measurements or safety
  • Inability to understand verbal and/or written explanation of the study requirements

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: Control de caso
  • Perspectivas temporales: Transversal

Cohortes e Intervenciones

Grupo / Cohorte
Case
Participants with a pack year history of more than 10 pack years, diagnosed with COPD who have FEV1/FVC ratio of less than 0.7 AND FEV1 predicted value less than or equal to 60%.
Control
Participants without a diagnosis of COPD who have a smoking history of more than 10 pack years

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Resting white and grey matter structural integrity
Periodo de tiempo: up to 12 weeks
Grey and white matter volume (mm3) using the MRI MPRAGE sequences will be measured at rest
up to 12 weeks
Cardiac structural integrity
Periodo de tiempo: up to 12 weeks
Cardiac output (L/min) will be measured using the MRI sequence (Short axis Cine) at rest.
up to 12 weeks
Cardiac structural integrity
Periodo de tiempo: up to 12 weeks
Cardiac fibrosis (%) will be measured using the MRI MOLLI T1 sequence at rest.
up to 12 weeks
Cardiac structural integrity
Periodo de tiempo: up to 12 weeks
Myocardial strain (%) will be measured using the MRI cardiac tagging sequence at rest.
up to 12 weeks
Whole body fat and muscle quantification
Periodo de tiempo: up to 12 weeks
Whole body fat and muscle quantification (%) will be measured using the MRI whole body mdixon sequence at rest.
up to 12 weeks
Aortic flow
Periodo de tiempo: up to 12 weeks
Aortic flow (ml/min) will be measured during rest, low level steady-state exercise and following cessation of exercise and compared between COPD and age and gender matched controls
up to 12 weeks
Cerebral blood flow
Periodo de tiempo: up to 12 weeks
Cerebral blood flow (ml/min) will be measured during rest, low level steady-state exercise and following cessation of exercise and compared between COPD and age and gender matched controls
up to 12 weeks
Cerebral perfusion
Periodo de tiempo: up to 12 weeks
Cerebral artery perfusion (ml/100g/min) will be measured during rest, low level steady-state exercise and following cessation of exercise and compared between COPD and age and gender matched controls
up to 12 weeks
Oxygen extraction fraction
Periodo de tiempo: up to 12 weeks
Oxygen extraction fraction (%) will be derived from the difference between arterial and venous cerebral oxygenation measured via TRUST MRI scan sequence during rest, low level steady-state exercise and following cessation of exercise and compared between COPD and age and gender matched controls
up to 12 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Muscle isometric strength (MVC)
Periodo de tiempo: up to 6 weeks
Isometric muscle torque of the quadriceps (Nm) assessed using the cybex dynamometer
up to 6 weeks
Muscle isokinetic fatigue
Periodo de tiempo: up to 6 weeks
Fatiguability test of the quadriceps (Nm) assessed using the cybex dynamometer
up to 6 weeks
Quality of life (SGRQ)
Periodo de tiempo: 1 week
Assessed using the St Georges Respiratory Questionnaire. min value: 0, max value: 84, higher score means worse outcome
1 week
Physical activity level (IPAQ Physical activity questionnaire)
Periodo de tiempo: 1 week
Assessed using the International Physical activity questionnaire. min value: 0, max value: 66000, higher score means better outcome
1 week
Montreal Cognitive Assessment (MoCA) cognition level
Periodo de tiempo: 1 week
Assessed using the Montreal cognitive assessment questionnaire. min value: 0, max value: 30, higher score means better outcome
1 week
Hospital anxiety and depression scale (HADS)
Periodo de tiempo: 1 week
min value: 0, max value: 21, higher score means worse outcome
1 week
Hand grip strength
Periodo de tiempo: 1 week
Composite of hand grip strength (Kg), measured by a hand held dynamometer,
1 week
Timed up and go test
Periodo de tiempo: 1 week
Timed up and go test (seconds) will be measured to assess degree of frailty.
1 week
Serum markers of inflammation for research purposes (likely to include IL-1, IL-6, and TNFα)
Periodo de tiempo: 1 week
Blood test
1 week
Heart rate response to exercise
Periodo de tiempo: up to 6 weeks
Heart rate response (Beats per minute) will be measured at rest and during incremental exercise to assess cardio-respiratory fitness.
up to 6 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Charlotte Bolton, NIHR Nottingham Biomedical Research Centre Respiratory theme, University of Nottingham

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

3 de enero de 2019

Finalización primaria (Anticipado)

30 de septiembre de 2020

Finalización del estudio (Anticipado)

30 de septiembre de 2020

Fechas de registro del estudio

Enviado por primera vez

17 de octubre de 2019

Primero enviado que cumplió con los criterios de control de calidad

22 de octubre de 2019

Publicado por primera vez (Actual)

24 de octubre de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de octubre de 2019

Última actualización enviada que cumplió con los criterios de control de calidad

28 de octubre de 2019

Última verificación

1 de octubre de 2019

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

Indeciso

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

3
Suscribir